Parkinson's disease-associated LRRK2 G2019S enhances intestinal neutrophil extracellular trap formation through RAB10–myeloperoxidase signaling and promotes enteric α-synuclein accumulation
This study demonstrates that the Parkinson's disease-associated LRRK2 G2019S mutation exacerbates intestinal inflammation and enteric α-synuclein accumulation by driving excessive neutrophil extracellular trap formation through a kinase-dependent RAB10–myeloperoxidase signaling axis.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Parkinson's disease is often thought of as a condition that begins in the brain, causing tremors and stiffness, but growing evidence suggests the trouble may start much earlier and much lower down: in the gut. For years, scientists have noticed that people with inflammatory bowel disease have a higher risk of developing Parkinson's later in life, and that the gut of a Parkinson's patient often contains clumps of a protein called alpha-synuclein, which is the same protein that forms damaging tangles in the brain. This has led to a theory that the disease might travel from the intestines up to the brain along the vagus nerve. A key genetic player in this story is a gene called LRRK2. When this gene carries a specific mutation, it becomes overactive and is a major risk factor for Parkinson's. While we know this overactive gene affects brain cells, researchers have been unsure how it influences the immune system in the gut, particularly a type of white blood cell called a neutrophil, which acts as a first responder to infection and injury.
A team of researchers at National Taiwan University and Academia Sinica set out to solve this puzzle by looking at what happens when the gut is inflamed in mice carrying the human Parkinson's-associated LRRK2 mutation. They wanted to know if this overactive gene changes how neutrophils behave in the intestine. The scientists induced gut inflammation in these mice using a chemical that irritates the colon, mimicking a condition similar to human inflammatory bowel disease. They found that the mice with the mutation developed more severe gut inflammation than their normal counterparts, but not because they had more immune cells rushing to the scene. Instead, the neutrophils that were already there were behaving differently. These cells were releasing massive, web-like structures made of DNA and toxic enzymes, known as neutrophil extracellular traps, or NETs. In the mice with the mutation, these traps were formed in much greater quantities, creating a toxic environment that worsened the gut damage and caused more of the harmful alpha-synuclein protein to build up in the intestinal wall.
To understand if these NETs were the cause of the extra damage, the researchers tried to break them down. They treated the mice with an enzyme that eats away the DNA in the traps, and they also bred mice that lacked a specific protein needed to make these traps. In both cases, the gut inflammation became less severe, and the buildup of the alpha-synuclein protein in the gut decreased significantly. This proved that the overactive gene was driving the disease not by recruiting more soldiers, but by turning the existing soldiers into overzealous attackers that released too much toxic webbing. The researchers then looked inside the cells to find the mechanism. They discovered that the overactive LRRK2 gene was phosphorylating, or chemically tagging, a small protein called RAB10. This tag acted like a switch, telling the cell to move a toxic enzyme called myeloperoxidase toward the DNA traps. Once there, this enzyme produced a powerful oxidant that helped the traps form and spread.
The study carefully ruled out several other possibilities. The researchers found that the extra NETs were not caused by a general increase in reactive oxygen species or by a different enzyme called neutrophil elastase, which had been suspected in other contexts. They also showed that the process depended on the presence of gut bacteria; when the mice were raised in a germ-free environment, the mutation no longer caused the excessive NET formation or the alpha-synuclein buildup. This confirmed that the interaction between the overactive gene, the immune cells, and the gut microbiome is essential for this specific pathway. The findings suggest a clear chain of events: the mutated gene makes the neutrophils hyper-sensitive, causing them to release too many toxic webs in response to gut bacteria, which in turn damages the gut lining and encourages the accumulation of the Parkinson's-linked protein.
This work provides a concrete link between a genetic risk factor for Parkinson's and a specific immune malfunction in the gut. It shows that the disease process might begin with a miscommunication between a gene and the immune system, leading to a toxic environment in the intestine that could eventually influence the brain. While the study does not prove that stopping this process will cure Parkinson's, it identifies a specific pathway involving the LRRK2 gene, the RAB10 protein, and the myeloperoxidase enzyme that could be targeted by future therapies. By understanding how a single genetic change alters the behavior of immune cells in the gut, scientists can begin to explore whether calming this specific immune response might prevent the early stages of the disease from taking hold.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.